Brief Articles
Copyright ©2009 The WJG Press and Baishideng.
World J Gastroenterol. Jan 21, 2009; 15(3): 328-333
Published online Jan 21, 2009. doi: 10.3748/wjg.15.328
Table 1 Characteristics of the study population
CharacteristicsTotal group (n = 301)
Age1 (yr)48.27 ± 11.79
Gender (%, M/F)57.5/42.5
Contamination mode (%)
Tranfusion27.2
Drug-addict26.9
Blood exposure accident7.6
Others38.2
Genotype (% with 1/2/3/4/5/ND)35/11/18/8/2/26
Stage of fibrosis (% with stage 0/1/2/3/4/ND)1/11/42/20/20/6
Type of treatment (%)
With IFNα3.3
Peg-interferon9.0
IFNα + ribavirin27.2
Peg-interferon + ribavirin60.4
Duration of treatment (mo)17.91 ± 3.78
TSH before treatment (MIU/L)11.54 ± 1.25
Positive antibodies before treatment
TPOAb12/229
TGAb8/227
TSHRAb1/95
Table 2 Classification of thyroid disorder and long-term normalisation of dysthyroidism (n = 30)
Type of dysthyroidism of normalisationDiscontinued treatmentNormalisationMean delay (mo)
Hyperthyroidism13997.44 ± 7.051
Silent thyroiditis5456.80 ± 3.701
Graves’ disease4215
NC2222.00 ± 1.411
Triphasic evolution21124
Hypothyroidism116310.67 ± 4.041
Autoimmune10528.50 ± 2.121
NC11115
Biphasic evolution63410.75 ± 5.501
Table 3 Features associated with dysthyroidism
With dysthyroidismWithout dysthyroidismP
Age1 (yr)46.20 ± 10.0848.49 ± 11.960.40
Female (%)56.940.90.05
Contamination mode (%)
Transfusion33.326.6
Drug-addict20.027.7
Blood exposure accident13.37.0
Others33.338.7
Genotype (%, 1/2/3/4/5/6/ND)57/13/13/0/0/0/1733/11/20/9/1/0/260.20
Stage of fibrosis < F2 (%)30.010.30.009
Type of treatment (%)
IFNα3.33.3
Peg-interferon6.79.3
IFNα + ribavirin16.728.5
Peg-interferon + ribavirin73.358.9
Duration of treatment1 (mo )7.73 ± 3.648.09 ± 3.930.30
Positive antibodies before treatment (%)
TPOAb26.92.5< 0.0003
TgAb18.51.50.0003
TSHRAb0.01.30.42